In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Peter Charlish

Principal analyst

Surrey, England
Peter originally trained as a pharmacologist and has been following the fortunes of the pharmaceutical and medtech industries for over 35 years. During that time he has interviewed many people, attended many conferences and trade shows, and has visited companies large and small. He has written items for newsletters, feature articles for magazines, as well as longer in-depth reports. He has also spoken on healthcare-related matters at a number of international conferences. Out of all that has come a passion to understand what drives individuals and organisations to push back the frontiers of knowledge for the overall benefit of mankind. In his spare time he likes to complain about falling standards (grammar, manners, road users who don’t indicate), and he has little time for those who use management gobbledegook.
Set Alert for Articles By Peter Charlish

Latest From Peter Charlish

Qiagen's Strategic Alliances, 2012–2017

The January deal with Singulex is just the latest in a long string of Qiagen's tie-ups with pharma and diagnostics partners. Herein, a five-year review of Qiagen's collaborations.

Diagnostics Medical Device

Singulex And Qiagen Partner In Personalized Medicine

Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.

Deals In Vitro Diagnostics

Flatiron Aims To Accelerate, Personalize Cancer Research

Flatiron Health was formed to exploit a previously untapped source of real-world data on the treatment and clinical outcomes of cancer patients. The company is now working with most of the major players in the oncology sector as well as with the FDA to maximize the benefits of such data analytics.

BioPharmaceutical Innovation

CGT Catapult Builds Cell/Gene Manufacturing Facility

The CTG Catapult aims to capture the commercial potential of the UK's cell and gene therapy research. To that end, it has constructed a GMP-compliant manufacturing facility in Stevenage.


Cell Therapy Manufacturing: Challenges Remain

If cell therapies are to realize their full potential, manufacturing procedures need to be in place to ensure their safety, potency and consistency at an economically sustainable cost. We aren't there yet, according to a panel at the Alliance for Regenerative Medicine's European Investor Day in London.

Innovation Manufacturing

StemCells Finds White Knight In Microbot

In May 2016, results from StemCell Inc.’s Phase II study of its only product still in development, a preparation of human neural stem cells for the treatment of chronic spinal cord injuries, suggested that there was little chance of the product ever becoming a commercial success. The company’s stock plummeted 80% overnight. Then, in August, when all appeared to be lost, StemCells announced that it was entering a strategic merger agreement with the Israeli company Microbot Medical Ltd., which researches and develops micro-robotic assisted medical technologies.

Medical Device Business Strategies
See All